野村发布研报称，上调荣昌生物今明两年净亏损预测分别1.3%及8%，以反映旗下两款上市产品RC18及RC48的销售上升，及因集团现金燃烧状况而增加的利息支出。该行预计，集团今年第三季销售额同比增长35%至4.7亿元人民币，净亏损为4.25亿元人民币，以反映销售正按计划上升。该行认为，公司或需进一步控制其运营支出。Rongchang Biotech (09995) is now down more than 4%. As of press release, it is down 4.63% to HK$14.82, with a turnover of HK$34.6409 million.
The Zhitong Finance App learned that Rongchang Biotech (09995) is now down more than 4%. As of press release, it is down 4.63% to HK$14.82, with a turnover of HK$34.6409 million.
According to the news, on October 15, Rongchang Biotech announced that its application for marketing the third indication of its original antibody-conjugated drug (ADC), verdicitumab (RC48, Edixi) was accepted by the Drug Evaluation Center of the State Drug Administration and included in the priority review and approval process. In addition, the results of a phase II clinical study of Rongchang Biovidizumab and cardonilizumab for the treatment of recurrent or metastatic cervical cancer (AK001) were first announced recently.
Nomura released a research report stating that Rongchang Biotech's net loss forecast for this year and next two years was raised by 1.3% and 8%, respectively, to reflect the increase in sales of its two listed products, RC18 and RC48, and increased interest expenses due to the Group's cash burning situation. The bank expects the Group's third quarter sales to increase 35% year-on-year to 0.47 billion yuan, with a net loss of 0.425 billion yuan to reflect the increase in sales as planned. The bank believes that the company may need to further control its operating expenses.
